

## Supplementary Methods

### Drug screen

SUM159 cells were seeded into 24-well ultra-low attachment plates (Corning, cat# 3473) at a density of 5,000 cells per well in serum-free DMEM/F-12 medium supplemented with 20 ng/mL basic FGF, 20 ng/mL EGF, 4 µg/mL insulin, 4 µg/mL heparin, 0.5 µg/mL hydrocortisone, 0.4% BSA and B27 (Invitrogen). Twenty-four hours after plating, cells were dosed with a library of 165 small molecule compounds purchased from LKT laboratories (St. Paul, MN) and Selleckchem (Houston, TX) at 5 µM final concentration in triplicates. Mammospheres were counted using an inverted microscope three days after drug treatments. Inhibition was calculated using the following method: % inhibition = (1 - Number of mammospheres generated from test compound-treated cells/Number of mammospheres from vehicle (DMSO)-treated cells) x 100.

### ESA<sup>+</sup>/CD44<sup>+</sup>/CD24<sup>-</sup> cell sorting

Tumorigenic breast CSCs have been shown to be enriched in the ESA<sup>+</sup>/CD44<sup>+</sup>/CD24<sup>-</sup> subpopulation (1). To isolate breast CSCs, flow cytometry based cell sorting was performed using method as previously described (1). Briefly, SUM159 or SUM149 cells were re-suspended in PBS containing 2%FBS at a concentration of 10<sup>6</sup> cells per 100 µl and incubated with FITC-conjugated mouse anti-human epithelial specific antigen (ESA), APC-conjugated mouse anti-human CD44 and BV421-conjugated mouse anti-human CD24 (all from BD Biosciences) for 20 min on ice. Cells were washed twice with PBS and re-suspended in 2%FBS/PBS before flow cytometry analysis. ESA<sup>+</sup>/CD44<sup>+</sup>/CD24<sup>-</sup> cells were sorted using a FACSAria III Cell Sorter (BD Biosciences).

### **Real-time reverse transcriptase-PCR (RT-PCR)**

Total cellular RNA was prepared using TRIzol reagent (Invitrogen). Quality and quantity of RNA samples were assessed using a Nanodrop spectrometer. First-strand cDNA was synthesized from 1 µg of total RNA using a High-Capacity cDNA Reverse Transcription Kit (ThermoFisher) according to the manufacturer's instructions. MYC mRNA expression levels were measured using TaqMan<sup>®</sup> Gene Expression Assay (ThermoFisher, Assay ID: Hs00153408\_m1) on a LightCycler<sup>®</sup> 480 System (Roche). Fold change in mRNA levels were calculated using the  $2^{-\Delta\Delta C_T}$  method and normalized to GAPDH (ThermoFisher, Assay ID: Hs99999905\_m1) levels as described previously (2).

### **Flow cytometric apoptosis assay**

Human TNBC cells were treated with compounds for 24 h and then stained with FITC-conjugated anti-Annexin V antibody and PI using a FITC Annexin V Apoptosis Detection Kit (BD Biosciences, cat# 556547) according to the manufacturer's protocol. Apoptotic cells were measured using a BD LSRFortessa<sup>™</sup> X-20 cell analyzer (Becton Dickinson, San Jose, CA) and FACSDiva<sup>™</sup> software. Data analysis was performed using FlowJo software (Tree Star, Ashland, OR).

### **Immunohistochemical analysis (IHC)**

Xenograft tumors were fixed with formalin and embedded in paraffin. Tissue sections (5 µm thick) were prepared. Endogenous peroxidase activity was blocked by incubation with 3 % hydrogen peroxide for 30 min and followed by heating in 1mM EDTA for antigen retrieval. The sections were then blocked with 5 % normal goat serum in 0.1 % Triton X-100/PBS for 1 h and

incubated overnight at 4 degree with rabbit anti-human c-Myc monoclonal antibody (1:200, cell signaling). After wash with PBS, slides were incubated with ABC reagent (Vector) for 30 min. Immunostaining was visualized by DAB and the slides were counterstained using hematoxylin.

### **Supplementary references**

1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. *Proc Natl Acad Sci U S A* 2003; 100: 3983-8.
2. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the  $2^{-\Delta\Delta C(T)}$  Method. *Methods* 2001; 25:402-8.